İnci Alacacıoğlu
- Co-authors
- Fatih DemırkanMehmet Ali ÖzcanAhmet AlacacıoğluBülent ÜndarÖmür Gökmen SevindikGüner Hayri ÖzsanAhmet DiricanBahriye Payzın
- Topics
- Multiple Myeloma Research and Treatments (8 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers)Lymphoma Diagnosis and Treatment (5 papers)
- Cited by
- HematologyOncologyGenetics
- Journals
- SHILAP Revista de lepidopterologíaBloodJournal of Thrombosis and Haemostasis
- Partner nations
- TürkiyeUnited StatesAustralia
In The Last Decade
İnci Alacacıoğlu
43 papers receiving 376 citations
Peers
Comparison fields: 5 of 63
- Oncology 157
- Hematology 123
- Genetics 61
- Molecular Biology 51
- Immunology 49
Countries citing papers authored by İnci Alacacıoğlu
This map shows the geographic impact of İnci Alacacıoğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by İnci Alacacıoğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites İnci Alacacıoğlu more than expected).
Fields of papers citing papers by İnci Alacacıoğlu
This network shows the impact of papers produced by İnci Alacacıoğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by İnci Alacacıoğlu. The network helps show where İnci Alacacıoğlu may publish in the future.
Co-authorship network of co-authors of İnci Alacacıoğlu
This figure shows the co-authorship network connecting the top 25 collaborators of İnci Alacacıoğlu. A scholar is included among the top collaborators of İnci Alacacıoğlu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with İnci Alacacıoğlu. İnci Alacacıoğlu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 7 | |
| 5 | 1 | |
| 6 | 3 | |
| 7 | 4 | |
| 8 | 3 | |
| 9 | 3 | |
| 10 | 5 | |
| 11 | 4 | |
| 12 | 35 | |
| 13 | 6 | |
| 14 | 23 | |
| 15 | 19 | |
| 16 | 11 | |
| 17 | 10 | |
| 18 | A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis. | 2 |
| 19 | Plasma Thrombin Activitable Fibrinolysis Inhibitor Levels in Behçet´s Disease | 2 |
| 20 | 10 |
About İnci Alacacıoğlu
İnci Alacacıoğlu is a scholar working on Hematology, Genetics and Oncology, having authored 46 papers that have together received 383 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Lymphoma Diagnosis and Treatment (5 papers). The work is most often cited by research in Hematology (123 citations), Oncology (157 citations) and Genetics (61 citations). İnci Alacacıoğlu has collaborated with scholars based in Türkiye, United States and Australia. Frequent co-authors include Fatih Demırkan, Mehmet Ali Özcan, Ahmet Alacacıoğlu, Bülent Ündar, Ömür Gökmen Sevindik, Güner Hayri Özsan, Ahmet Dirican, Bahriye Payzın, Ünsal Yılmaz and Hayri Özsan. Their work appears in journals such as SHILAP Revista de lepidopterología, Blood and Journal of Thrombosis and Haemostasis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.